CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 7 enrolled
Drug / intervention
(-)-epicatechindrug
Likely dose
(-)-epicatechin 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01856868
NCT01856868Phase 2Completed
CompareCT.gov

An Open-label Pilot Study of Purified Tea-derived Epicatechin to Improve Mitochondrial Function, Strength and Skeletal Muscle Exercise Response in Becker Muscular Dystrophy.

Craig McDonald, MD·interventional·Posted May 17, 2013·Updated Dec 22, 2021

In Brief

A Phase 2 clinical trial evaluating (-)-epicatechin for Becker Muscular Dystrophy. Completed, enrolled 7 participants across 1 site.

Detailed Summary

(-)-Epicatechin will be evaluated for the treatment of progressive muscle loss and impaired skeletal muscle function in Becker Muscular Dystrophy (BMD) patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBecker Muscular Dystrophy
CountriesUnited States
CollaboratorsCardero Therapeutics, Inc.

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMay 17, 2013
Enrollment StartMay 1, 2013
Primary CompletionSep 1, 2018
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 13.1 years ago

Interventions

(-)-epicatechindrug

purified nutritional extract (-)-epicatechin 100mg/day orally for 8 weeks.